Antileukemic Effect of Venetoclax and Hypomethylating Agents Via Caspase-3/GSDME-mediated Pyroptosis

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2023 Sep 7

PMID 37679782

Authors

Fanghua Ye

Wen Zhang

Chenying Fan

Jiajia Dong

Min Peng

Wenjun Deng

Hui Zhang

Liangchun Yang

Affiliations

Soon will be listed here.

Abstract

Background: The identifying of B-cell lymphoma 2 (Bcl-2) as a therapeutic target has led to a paradigm shift in acute myeloid leukemia (AML) treatment. Pyroptosis is a novel antitumor therapeutic mechanism due to its cytotoxic and immunogenic effects. The combination of venetoclax and hypomethylating agents (HMAs) has been shown to lead to durable responses and significantly improve prognosis in patients with AML. However, our understanding of the mechanisms underlying this combinatorial activity is evolving.

Methods: We investigated whether the Bcl-2 inhibitor venetoclax induces AML cell pyroptosis and identified pyroptosis effector proteins. Via using western blotting, immunoprecipitation, RNA interference, CCK8 assays, and LDH assays, we explored the mechanism underlying the pyroptotic effect. The relationship between the expression of the pyroptosis effector protein GSDME and AML prognosis was investigated. The effect of GSDME demethylation combined with venetoclax treatment on pyroptosis was investigated and confirmed in mouse models and clinical samples.

Results: Venetoclax induces pyroptosis that is mediated by caspase-3-dependent GSDME cleavage. Mechanistically, venetoclax upregulates caspase-3 and GSDME cleavage by activating the intrinsic apoptotic pathway. GSDME is downregulated in AML by promoter methylation, and low GSDME expression is significantly associated with poor prognosis, based on public databases and patient sample analysis. In vivo and in vitro experiments showed that GSDME overexpression or HMAs-mediated restoration of GSDME expression significantly increased venetoclax-induced pyroptosis in AML.

Conclusion: GSDME-mediated pyroptosis may be a novel aspect of the antileukemic effect of Bcl-2 inhibitors. This finding offers new insights into potential biomarkers and therapeutic strategies, identifying an important mechanism explaining the clinical activity of venetoclax and HMAs in AML.

Citing Articles

A novel prognostic model based on pyroptosis signature in AML.

Zhang H, Zhu H, Sheng Y, Cheng Z, Peng H Heliyon. 2024; 10(17):e36624.

PMID: 39263179 PMC: 11387551. DOI: 10.1016/j.heliyon.2024.e36624.

TREM2, a critical activator of pyroptosis, mediates the anti‑tumor effects of piceatannol in uveal melanoma cells via caspase 3/GSDME pathway.

Jiu X, Li W, Liu Y, Liu L, Lu H Int J Mol Med. 2024; 54(5).

PMID: 39219277 PMC: 11410308. DOI: 10.3892/ijmm.2024.5420.

[Research Progress on the Role of GSDME-mediated Pyroptosis in the Treatment of  Lung Cancer].

Li H, Tang X Zhongguo Fei Ai Za Zhi. 2024; 27(7):529-534.

PMID: 39147707 PMC: 11333950. DOI: 10.3779/j.issn.1009-3419.2024.106.17.

Case report: Clinical features of pediatric acute myeloid leukemia presenting with cardiac tamponade: a case series study and literature review.

Li T, Tang X, He X, Zhang L, Zhang Y, Wang L Front Oncol. 2024; 14:1391768.

PMID: 38939339 PMC: 11208300. DOI: 10.3389/fonc.2024.1391768.

Gasdermin-mediated pyroptosis confers anticancer immunity.

Lin W, Lin B, Zhou Q, Teng L J Immunother Cancer. 2024; 12(1).

PMID: 38212120 PMC: 10806534. DOI: 10.1136/jitc-2023-008162.

References

Broz P, Pelegrin P, Shao F . The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2019; 20(3):143-157. DOI: 10.1038/s41577-019-0228-2. View

Zhou B, Zhang J, Liu X, Chen H, Ai Y, Cheng K . Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. Cell Res. 2018; 28(12):1171-1185. PMC: 6274649. DOI: 10.1038/s41422-018-0090-y. View

Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki M . Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018; 103(9):e404-e407. PMC: 6119155. DOI: 10.3324/haematol.2018.188094. View

Lindsay J, Degli Esposti M, Gilmore A . Bcl-2 proteins and mitochondria--specificity in membrane targeting for death. Biochim Biophys Acta. 2010; 1813(4):532-9. DOI: 10.1016/j.bbamcr.2010.10.017. View

Kim M, Lebron C, Nagpal J, Chae Y, Chang X, Huang Y . Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochem Biophys Res Commun. 2008; 370(1):38-43. PMC: 3094717. DOI: 10.1016/j.bbrc.2008.03.026. View

Hafezi S, Rahmani M . Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives. Cancers (Basel). 2021; 13(6). PMC: 8001391. DOI: 10.3390/cancers13061292. View

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

Yu J, Li S, Qi J, Chen Z, Wu Y, Guo J . Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 2019; 10(3):193. PMC: 6389936. DOI: 10.1038/s41419-019-1441-4. View

Torre-Minguela C, Gomez A, Couillin I, Pelegrin P . Gasdermins mediate cellular release of mitochondrial DNA during pyroptosis and apoptosis. FASEB J. 2021; 35(8):e21757. DOI: 10.1096/fj.202100085R. View

10.

Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y . Pyroptosis: A new frontier in cancer. Biomed Pharmacother. 2019; 121:109595. DOI: 10.1016/j.biopha.2019.109595. View

11.

Truong Nguyen L, Troadec E, Kalvala A, Kumar B, Hoang D, Viola D . The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. J Cell Physiol. 2019; 234(8):14040-14049. PMC: 8852851. DOI: 10.1002/jcp.28091. View

12.

De Schutter E, Croes L, Ibrahim J, Pauwels P, Op de Beeck K, Vandenabeele P . GSDME and its role in cancer: From behind the scenes to the front of the stage. Int J Cancer. 2020; 148(12):2872-2883. DOI: 10.1002/ijc.33390. View

13.

Cookson B, Brennan M . Pro-inflammatory programmed cell death. Trends Microbiol. 2001; 9(3):113-4. DOI: 10.1016/s0966-842x(00)01936-3. View

14.

Jonas B, Pollyea D . How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019; 33(12):2795-2804. DOI: 10.1038/s41375-019-0612-8. View

15.

Schoofs T, Berdel W, Muller-Tidow C . Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia. 2013; 28(1):1-14. DOI: 10.1038/leu.2013.242. View

16.

Wang Y, Gao W, Shi X, Ding J, Liu W, He H . Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017; 547(7661):99-103. DOI: 10.1038/nature22393. View

17.

Niswander L, Chung P, Diorio C, Tasian S . Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax. Haematologica. 2023; 108(11):3142-3147. PMC: 10620590. DOI: 10.3324/haematol.2022.282637. View

18.

Bose P, Gandhi V, Konopleva M . Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017; 58(9):1-17. PMC: 5478500. DOI: 10.1080/10428194.2017.1283032. View

19.

Akino K, Toyota M, Suzuki H, Imai T, Maruyama R, Kusano M . Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci. 2006; 98(1):88-95. PMC: 11158324. DOI: 10.1111/j.1349-7006.2006.00351.x. View

20.

Wei A, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I . Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022; 140(25):2754-2756. DOI: 10.1182/blood.2022016963. View